[Risk factor analysis of early recurrence after resection of XXXX ].

@entity1 @entity3 @entity5 @entity14
OBJECTIVE: To explore the role of repeat liver resection in @entity14 ( @entity14 ) with early recurrence and to analyze the risk factors of early recurrence. METHODS: Clinicopathological and follow-up data of 303 @entity14 @entity1 undergoing liver resection in our department between January 2000 and August 2014 were analyzed retrospectively. The 5-year overall survivals between early recurrence(within postoperative 1 year) and non-early recurrence were compared. The impact of repeat liver resection on 5-year survival of early recurrence was analyzed. Clinicopathological features which might be associated with early recurrence were investigated using univariate and multivariate analyses. RESULTS: Among 303 @entity1 , 192(63.4%) @entity1 had recurrence, including 145 @entity1 of early recurrence and 47 of non-early recurrence. The 5-year overall survival of early recurrence @entity1 was significantly lower compared with non-early recurrence ones(16.0% vs. 63.9%, P=0.000). Among 145 early recurrence @entity1 , 80 were evaluated as resectable, of whom 22 received repeat liver resection. Compared with other 58 @entity1 receiving conservative treatment, above 22 @entity1 receiving repeat liver resection had a significantly higher 5-year overall survival(27.1% vs. 0%, P=0.033). Multivariate analysis revealed @entity5 , lymph node @entity3 , and larger size(> 5 cm) of metastatic liver focus were independent risk factors of early recurrence, and good efficacy of neo-adjuvant chemotherapy was independent protective factor of early recurrence(all P<0.05). Repeat liver resection was associated with better long-term survival. CONCLUSIONS: The prognosis of early recurrence after liver resection in @entity14 @entity1 is poor, while repeat resection for resectable lesions in recurrence @entity1 can obviously prolong the survival. For those with late T-stage, lymph node @entity3 , and larger metastatic liver focus, actively preoperative neo-adjuvant chemotherapy should be considered.
